Homeopathic Regulation Critics Will Swing For Change Against Industry Stalwarts At FDA Hearing
This article was originally published in The Tan Sheet
Executive Summary
In addition to marketers and trade groups, Gary Yingling, a former FDA counsel involved in the agency’s decision to omit homeopathics from the OTC drug review, will make a presentation at a public hearing April 20-21. FDA’s current approach as “a rational framework,” CHPA says.
You may also be interested in...
Science-Based Evaluation Advocates Want Tighter Homeopathic Oversight
Public health concerns should prompt FDA to tighten its regulation of homeopathic drugs, a citizen petition filed by the nonprofit Center for Inquiry says.
GNC, Rite Aid expansion plans
GNC and Rite Aid announce Aug. 7 an agreement that will nearly double the number of GNC LiveWell locations within Rite Aid stores nationwide by 2014. Under the contract, the firms expect 1,125 GNC locations to be added to the 1,300 currently operating inside Rite Aid stores; the agreement also provides Rite Aid with an option to extend the contract through 2019 and open 250 more stores during that time period. Rite Aid plans to add "several hundred" GNC store-within-Rite Aid store locations during its fiscal year, ending March 1, 2008...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”